Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.

The collaboration will employ KineMed’s unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

Diabetes is an emerging global healthcare epidemic with an estimated 347 million people affected, according to the WHO. Diabetes is predicted to become the seventh leading cause of death in the world by the year 2030 and total deaths from diabetes are projected to rise by more than 50% in the next 10 years.

In the United States Type II diabetes affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations and new cases of blindness among adults.

Despite 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.

“We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform,” said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. “We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
Ginger Nanoparticles Heal Bowel Disease
Lab team spins ginger into nanoparticles to heal inflammatory bowel disease.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
Exosome Research and Quality Control Using ZetaView
Particle Matrix's ZetaView particle characterisation system used by Cell Guidance Systems for exosome research.
Natural Metabolite Can Suppress Inflammation
An international group of scientists from US, Canada, Germany and Russia has revealed a substance produced in humans that can suppress the pro-inflammatory activity of macrophages – specific cells of immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!